Isaac Health lands $5.7m to target ‘dementia neurology deserts’

Virtual brain health provider screens, diagnoses and treats brain health conditions, with a focus on dementia.

Digital health company Isaac Health has secured a $5.7 million seed funding round to advance its mission to address gaps in brain health care in the US. Founded in 2022, the New York based company provides virtual brain health and memory clinic services with the aim of enhancing access to limited brain health resources.

Isaac Health claims that more than 20 US states are considered “dementia neurology deserts,” where a substantial portion of dementia and mild cognitive impairment cases remains undiagnosed. In addition, the company says that recent progress in disease-modifying therapies for early-stage Alzheimer’s disease accentuates the need for specialist evaluation and follow-up.

Isaac Health is aiming to change how brain healthcare is delivered by leveraging advanced technology and predictive machine learning to identify patients with various cognitive and brain health conditions. Collaborating with health systems and payers, the company is focused on screening, diagnosing, treating, and managing individuals with brain health conditions, particularly dementia.

Founded by Dr Joel Salinas, a Harvard-trained neurologist and former Assistant Professor of Neurology at the Massachusetts General Hospital, Isaac Health will use the funding to scale operations and establish strategic partnerships, as well as enhance its brain health provider platform.

“This funding will enable us to accelerate our mission of providing high-quality patient-centered care for the evaluation and management of dementia and many other brain health conditions,” said Julius Bruch, CEO of Isaac Health.

The oversubscribed funding round was co-led by Meridian Street Capital and B Capital, with participation from investors including Primetime Partners, Co-Found Partners, VU Venture Partners, and AirAngels.

“We are currently at a historic inflection point for brain health with the first full FDA-approved disease modifying treatment for early-stage Alzheimer’s disease, and the company’s commitment to innovation, coupled with the vast potential size of the brain health market, strongly aligns with our vision for the future of healthcare,” said Karen Page, General Partner at B Capital.

“Brain health should mean more than just supporting the late stages of disease,” said George Ribaroff, Partner at Meridian Street Capital. “It should mean early detection and proactive care, in and beyond the four walls of a clinic.”